Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subvisible Retinal Laser Therapy vs Intravitreal Bevacizumab in Diabetic Macular Edema
NCT02229175Phase 3Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Jan 2021
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in diabetic macular edema (DME) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Retinal thickness at 12 months. Planned start Jan 2021; status: withdrawn.
02
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02229175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229175.